Pfizer Nurtec ODT/Vydura — Revenues: decreased by 12.8% to $353.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 42.3%, from $248.00M to $353.00M.
pfe_segment_nurtec_odt_vydura_revenues| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $1.00M | $0.00 | $0.00 | $212.00M | $167.00M | $247.00M | $233.00M | $282.00M | $178.00M | $356.00M | $337.00M | $393.00M | $248.00M | $359.00M | $412.00M | $405.00M | $353.00M |
| QoQ Change | — | — | — | — | -100.0% | — | — | -21.2% | +47.9% | -5.7% | +21.0% | -36.9% | +100.0% | -5.3% | +16.6% | -36.9% | +44.8% | +14.8% | -1.7% | -12.8% |
| YoY Change | — | — | — | — | — | — | — | >999% | — | — | +33.0% | +6.6% | +44.1% | +44.6% | +39.4% | +39.3% | +0.8% | +22.3% | +3.1% | +42.3% |